NIH awards $25M+ contract to Venatorx Pharmaceuticals for novel antibiotic research targeting drug-resistant bacteria

Contract Overview

Contract Amount: $25,044,893 ($25.0M)

Contractor: Venatorx Pharmaceuticals Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2020-07-01

End Date: 2027-01-18

Contract Duration: 2,392 days

Daily Burn Rate: $10.5K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 12

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.

Place of Performance

Location: MALVERN, CHESTER County, PENNSYLVANIA, 19355

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $25.0 million to VENATORX PHARMACEUTICALS INC for work described as: TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. Key points: 1. Contract focuses on developing a new class of antibiotics to combat multidrug-resistant Acinetobacter baumannii. 2. Research and Development in Physical, Engineering, and Life Sciences sector. 3. Full and open competition indicates a broad market search for qualified contractors. 4. Contract duration of nearly 2400 days suggests a long-term, complex research effort. 5. Cost Plus Fixed Fee contract type may incentivize efficient research while managing costs. 6. Potential for significant public health impact by addressing a critical unmet medical need.

Value Assessment

Rating: good

The contract value of over $25 million for a multi-year R&D effort in a specialized area like antibiotic development appears reasonable. Benchmarking against similar NIH grants for early-stage drug discovery and development suggests this funding level is within expected ranges for complex biological research. The Cost Plus Fixed Fee structure allows for flexibility in research while providing a defined profit margin, which is common for high-risk, high-reward scientific endeavors.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, suggesting that multiple vendors were likely solicited and evaluated. The presence of 12 bids indicates a competitive process, which generally leads to better pricing and innovation. This level of competition is positive for price discovery and ensures that the government is likely receiving proposals from capable and cost-effective sources.

Taxpayer Impact: A competitive award process helps ensure that taxpayer dollars are used efficiently by driving down costs and encouraging the best possible solutions for critical public health challenges.

Public Impact

The primary beneficiaries are patients at risk of or suffering from infections caused by multidrug-resistant Acinetobacter baumannii. Services delivered include advanced research and development for a novel beta-lactamase inhibitor. Geographic impact is national, with potential global implications for combating antibiotic resistance. Workforce implications include support for highly skilled scientists and researchers in the biotechnology and pharmaceutical sectors.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Long-term R&D projects carry inherent risks of scientific failure or delays.
Reliance on a single contractor for this critical research could pose a risk if performance falters.
The effectiveness of the developed inhibitor will require extensive clinical trials beyond this contract's scope.

Positive Signals

Focus on a critical public health threat (MDR-Acinetobacter baumannii) addresses a significant unmet need.
Full and open competition suggests a robust selection process and potential for innovation.
The contract's duration and funding indicate a serious commitment to advancing this promising research area.

Sector Analysis

This contract falls within the Biotechnology and Pharmaceutical R&D sector, a critical area for public health and national security. The market for novel antibiotics is challenging due to high development costs and the rapid emergence of resistance. Government funding, particularly through agencies like NIH, plays a vital role in de-risking early-stage research and incentivizing private sector innovation in areas with limited commercial viability but high societal benefit. Comparable spending benchmarks are difficult to establish precisely due to the specialized nature of drug development, but significant investments are typical for promising therapeutic candidates.

Small Business Impact

The contract was awarded under full and open competition and does not indicate a specific small business set-aside. While Venatorx Pharmaceuticals Inc. may be a small or large business, the primary focus of this award appears to be on technical capability rather than small business participation. Subcontracting opportunities for small businesses may arise if Venatorx engages external specialized services, but this is not explicitly detailed in the award information.

Oversight & Accountability

Oversight for this contract is likely managed by the National Institutes of Health (NIH), a component of the Department of Health and Human Services. The contract type (Cost Plus Fixed Fee) typically involves regular financial and progress reporting from the contractor. Specific oversight mechanisms would include periodic reviews of research progress, adherence to scientific protocols, and financial accountability. Transparency is generally maintained through public award databases and scientific publications resulting from the research.

Related Government Programs

National Institute of Allergy and Infectious Diseases (NIAID) research grants
Biomedical Advanced Research and Development Authority (BARDA) funding
Department of Defense research on infectious diseases
National Center for Advancing Translational Sciences (NCATS) programs

Risk Flags

Scientific Risk
Development Timeline Risk
Market Viability Risk
Regulatory Approval Risk

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $25.0 million to VENATORX PHARMACEUTICALS INC. TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.

Who is the contractor on this award?

The obligated recipient is VENATORX PHARMACEUTICALS INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $25.0 million.

What is the period of performance?

Start: 2020-07-01. End: 2027-01-18.

What is the specific scientific approach Venatorx Pharmaceuticals is taking to develop this beta-lactamase inhibitor?

The contract aims to advance a novel beta-lactamase inhibitor targeting penicillin-binding proteins (PBPs) to combat multidrug-resistant Acinetobacter baumannii. Beta-lactamase inhibitors are designed to protect beta-lactam antibiotics (like penicillins and cephalosporins) from being broken down by enzymes called beta-lactamases, which are produced by bacteria to resist these drugs. By inhibiting these enzymes, the drug can effectively kill the bacteria. Acinetobacter baumannii is a particularly concerning pathogen due to its high levels of resistance to many existing antibiotics. The specific mechanism involving PBPs suggests a targeted approach to disrupt bacterial cell wall synthesis, a common vulnerability for bacteria.

How does the $25 million funding compare to typical R&D investments in antibiotic development?

The $25 million awarded by NIH is a significant sum for a single research contract, reflecting the complexity and long-term nature of antibiotic development. Early-stage drug discovery and preclinical research can range from a few million to tens of millions of dollars, depending on the novelty of the target and the required research activities. Phase I clinical trials alone can cost upwards of $10-20 million. Given that this contract likely covers advanced preclinical and potentially early clinical development, the funding appears aligned with industry benchmarks for high-potential therapeutic candidates in a challenging field. However, the total cost to bring a new antibiotic to market can easily reach hundreds of millions or even billions of dollars.

What are the primary risks associated with this contract and the development of new antibiotics?

The primary risks are scientific and financial. Scientifically, the research may not yield a viable drug candidate due to unforeseen biological challenges, lack of efficacy, or toxicity issues. The development of resistance mechanisms by bacteria is also a constant threat. Financially, antibiotic development is notoriously difficult due to high failure rates, long development timelines, and limited market returns compared to drugs for chronic conditions. This contract mitigates some financial risk through government funding, but the overall commercial viability post-development remains a significant hurdle for the pharmaceutical industry.

What is Venatorx Pharmaceuticals' track record in antibiotic research and development?

Venatorx Pharmaceuticals has a notable track record in developing novel antibiotics, particularly those targeting resistant bacteria. They have previously received significant funding and attention for their work on beta-lactamase inhibitors, including compounds like avibactam (in partnership with Pfizer) and their own pipeline candidates. Their focus aligns directly with the objectives of this NIH contract, suggesting they possess the necessary expertise and infrastructure. Their pipeline includes compounds aimed at combating Gram-negative pathogens, which are a major public health concern due to rising antimicrobial resistance.

How does this contract fit into the broader federal strategy for combating antimicrobial resistance (AMR)?

This contract is a key component of the broader federal strategy to combat Antimicrobial Resistance (AMR). Agencies like NIH, CDC, FDA, and BARDA collaborate on initiatives outlined in the National Action Plan for Combating Antimicrobial-Resistant Bacteria. NIH's role, as exemplified by this award, is crucial in funding basic and translational research to discover and develop new diagnostics, treatments, and prevention strategies. By investing in novel therapies like the beta-lactamase inhibitor, the government aims to replenish the dwindling pipeline of effective antibiotics and address the growing threat posed by drug-resistant infections.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: HHS-NIH-NIAID-BAA2019-1

Offers Received: 12

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 30 SPRING MILL DR, MALVERN, PA, 19355

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $44,503,614

Exercised Options: $25,044,893

Current Obligation: $25,044,893

Actual Outlays: $12,527,630

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline